Synthetic Biologics Inc. [AMEX: SYN] closed the trading session at $0.71 on 04/01/21. The day’s price range saw the stock hit a low of $0.69, while the highest price level was $0.74. The company report on April 1, 2021 that Synthetic Biologics Announces First Six Participants Dosed in Phase 1a Clinical Trial of SYN-020 Intestinal Alkaline Phosphatase.
A Multiple-Ascending Dose Study is on Track to Begin in Q3 2021.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
Phase 1 Clinical Program Intended to Support Development of SYN-020 in Multiple Indications, Including Treatment of Celiac Disease, Non-Alcoholic Fatty Liver Disease and Age-Related Metabolic and Inflammatory diseases.
The stocks have a year to date performance of 85.51 percent and weekly performance of 1.50 percent. The stock has been moved at 49.67 percent over the last six months. The stock has performed 10.24 percent around the most recent 30 days and changed 70.38 percent over the most recent 3-months.
If compared to the average trading volume of 23.61M shares, SYN reached to a volume of 8312144 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Synthetic Biologics Inc. [SYN]:
FBR & Co. have made an estimate for Synthetic Biologics Inc. shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on January 06, 2017. While these analysts kept the previous recommendation, FBR Capital raised their target price from $10 to $9. The new note on the price target was released on May 06, 2016, representing the official price target for Synthetic Biologics Inc. stock. Previously, the target price had yet another raise to $10, while FBR Capital analysts kept a Outperform rating on SYN stock.
The Average True Range (ATR) for Synthetic Biologics Inc. is set at 0.08
SYN stock trade performance evaluation
Synthetic Biologics Inc. [SYN] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 1.50. With this latest performance, SYN shares gained by 10.24% in over the last four-week period, additionally plugging by 49.67% over the last 6 months – not to mention a rise of 149.39% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SYN stock in for the last two-week period is set at 48.29, with the RSI for the last a single of trading hit 49.15, and the three-weeks RSI is set at 48.75 for Synthetic Biologics Inc. [SYN]. The present Moving Average for the last 50 days of trading for this stock 0.7953, while it was recorded at 0.6759 for the last single week of trading, and 0.5536 for the last 200 days.
Synthetic Biologics Inc. [SYN]: An insightful look at the core fundamentals
Return on Total Capital for SYN is now -113.27, given the latest momentum, and Return on Invested Capital for the company is -87.12. Return on Equity for this stock declined to -89.69, with Return on Assets sitting at -78.32. When it comes to the capital structure of this company, Synthetic Biologics Inc. [SYN] has a Total Debt to Total Equity ratio set at 5.89. Additionally, SYN Total Debt to Total Capital is recorded at 5.56, with Total Debt to Total Assets ending up at 5.62.
Reflecting on the efficiency of the workforce at the company, Synthetic Biologics Inc. [SYN] managed to generate an average of -$1,004,300 per employee.Synthetic Biologics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.70 and a Current Ratio set at 2.70.
Earnings per share (EPS) analysis for Synthetic Biologics Inc. [SYN] stock
With the latest financial reports released by the company, Synthetic Biologics Inc. posted -0.2/share EPS, while the average EPS was predicted by analysts to be reported at -0.27/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 25.90%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for SYN.
Synthetic Biologics Inc. [SYN]: Insider Ownership positions
There are presently around $1 million, or 1.50% of SYN stock, in the hands of institutional investors. The top three institutional holders of SYN stocks are: RENAISSANCE TECHNOLOGIES LLC with ownership of 1,237,733, which is approximately 43.967% of the company’s market cap and around 1.77% of the total institutional ownership; FISHER ASSET MANAGEMENT, LLC, holding 125,698 shares of the stock with an approximate value of $89000.0 in SYN stocks shares; and BRIDGEWAY CAPITAL MANAGEMENT, LLC, currently with $78000.0 in SYN stock with ownership of nearly 0% of the company’s market capitalization.
Positions in Synthetic Biologics Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 7 institutional holders increased their position in Synthetic Biologics Inc. [AMEX:SYN] by around 579,838 shares. Additionally, 6 investors decreased positions by around 102,113 shares, while 11 investors held positions by with 1,163,747 shares. The mentioned changes placed institutional holdings at 1,845,698 shares, according to the latest SEC report filing. SYN stock had 2 new institutional investments in for a total of 120,090 shares, while 3 institutional investors sold positions of 109 shares during the same period.